Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Nerve fiber conduction is the passage of electrical signals (action potentials) along nerve fibers (axons). The process relies on the rapid change in the membrane potential mediated primarily by voltage-gated sodium and potassium channels as well as the sodium-potassium ATPase pump[2][3][6]. Nerve fibers are classified as myelinated or unmyelinated: - In myelinated fibers, conduction velocity is greatly increased via saltatory conduction, where the action potential "jumps" between nodes of Ranvier[7][1]. - In unmyelinated fibers, conduction is slower and continuous, determined by channel density and axonal diameter[4][1]. Signal transmission between neurons occurs at synapses and can be chemical (involving neurotransmitter release and postsynaptic ion channel opening) or electrical (via gap junctions)[5]. Drugs that affect nerve fiber conduction do so by acting on ion channels (such as sodium, potassium, or calcium channels): - Sodium channel blockers (e.g., local anesthetics, antiarrhythmics, antiepileptics) reduce axonal excitability and block conduction. - Sodium channel gain-of-function mutations have been linked to pain syndromes; loss-of-function to insensitivity to pain[8]. Altered nerve conduction (slowed, blocked, or heightened) is a clinical marker for various neurological diseases but is not itself a drug target. Nerve conduction velocity is measured clinically, but is not a biomarker for a specific molecule. No direct safety concerns specific to the process; drugs that alter conduction (e.g. sodium channel blockers) have their own risks. Summary: "Nerve fiber conduction" does not refer to a single molecular entity or drug target; it is a physiological process mediated by ion channels (sodium, potassium, calcium), supported by the myelin sheath, and subject to modulation by various diseases and drugs[1][2][3][4][5][6][7][8]. For structured data extraction, the process should be mapped to specific ion channels (such as voltage-gated sodium channels (NaV)) or myelin-related proteins if a true drug target is intended.
Drugs modulate nerve fiber conduction by acting on ion channels (e.g., voltage-gated sodium, potassium, or calcium channels) or other components involved in the process, but the process itself does not have a single mechanism of action for direct targeting. For example, sodium channel blockers reduce axonal excitability.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Nerve fiber conduction.